Experimental antioxidant biotherapy for protection of the vascular wall by modified forms of superoxide dismutase and catalase

Current Pharmaceutical Design

Volumn 11, Issue 16, 2005, Pages 2007-2016

  Maksimenko, Alexander V ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Antioxidant therapy; Antithrombotic effect; Catalase; Chondroitin sulphate; Enzyme modification; Glycosaminoglycan; Superoxide dismutase; Thrombolysis; Thrombosis; Vascular wall

Indexed keywords

ANTICOAGULANT AGENT; ANTIOXIDANT; CATALASE; CHONDROITIN SULFATE; CHONDROITIN SULFATE PLUS CATALASE; CREATINE KINASE; DRUG CARRIER; ENDOTHELIUM DERIVED RELAXING FACTOR; FIBRINOLYTIC AGENT; FICOLL; GLYCOSAMINOGLYCAN; HYDROGEN PEROXIDE; PROSTACYCLIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; SARUPLASE; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE CHONDROITIN SULFATE; SUPEROXIDE DISMUTASE CHONDROITIN SULFATE PLUS CATALASE; SUPEROXIDE DISMUTASE MACROGOL; TAPROSTIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTICOAGULATION; ARTERY BLOOD FLOW; ARTERY OCCLUSION; ARTERY THROMBOSIS; BLOOD CLOT LYSIS; BLOOD VESSEL WALL; BOLUS INJECTION; CARDIOVASCULAR DISEASE; CREATINE KINASE BLOOD LEVEL; DISEASE MODEL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BINDING; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ENZYME MODIFICATION; GLYCOCALYX; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; VIRUS MYOCARDITIS;

ANIMALS; ANTIOXIDANTS; BLOOD VESSELS; CATALASE; CHONDROITIN SULFATES; HUMANS; SUPEROXIDE DISMUTASE; TECHNOLOGY, PHARMACEUTICAL;

EID: 20044383235     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054065756     Document Type: Review

References (94)

1. Becker RC. Thrombolytic agents and anticoagulants. Cardiovasc Drugs Ther 1993; 7: 825-8.
2. Folts JD. Drugs for prevention of coronary thrombosis: from animal model to clinical trial. Cardiovase Drugs Ther 1995; 9: 31-43.
3. Hirsh H, Weitz JI. New antithrombotic agents. Lancet 1999; 353: 1431-6.
4. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993; 22 (Suppl 4): S1-S14.
5. Topol E. Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 1995; 75: 27B-33B.
6. Schumacher WA, Heran CL, Steinbacher TE, Megill JR, Bird JE, Giancarli MR, et al. Thrombin inhibition compared with other antithrombotic drugs in rats. Thromb Res 1992; 68: 157-66.
7. Broersma RJ, Kutcher LW, Heminger EF. The effect of thrombin inhibition in rat arterial thrombosis model. Thromb Res 1991; 64: 405-12.
8. Schumacher WA, Heran CL, Steinbacher TE, Youssef S, Ogletree ML. Superior activity of thromboxane receptor antagonist as compared with aspirin in rat model of arterial and venous thrombosis. J Cardivasc Pharmacol 1993; 22: 526-33.
9. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994; 344: 721-4.
10. Gutteridge JMC, Halliwell B. Reoxygenation injury and antioxidant protection: a tale of two paradoxes. Arch Biochem Biophys 1990; 283: 223-6.
11. Niki E, Noguchi N. Effect of antioxidants against atherosclerosis. Mol Cell Biochem 2002; 234/235: 19-25.
12. Munzel T, Keaney JF Jr. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001; 104: 1571-4.
13. Maksimenko AV, Golubykh VL, Tischenko EG. Catalase and chondroitin sulphate derivatives against thrombotic effect induced by reactive oxygen species in a rat artery. Metabol Eng 2003; 5: 177-82.
14. Maksimenko AV, Tischenko EG, Golubykh VL. Antithrombotic activity of the superoxide dismutase-chondroitin sulphate complexes in a rat model of artery injury. Cardiovasc Drugs Ther 1999; 13: 479-84.
15. Berger HC, Frangakis CJ Jr. New Pharmazeutishe Anwendung. Patent Application. DE 3715662 A1, 1987.
16. Mehta JL, Nichols WW, Saldeen TGP, Chandna VK, Nicolini FA, Lawson DL, et al. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator. J Cardiovasc Pharmacol 1990; 16: 112-20.
17. Kumari R, Dikshit M, Srimal RC. Free radical scavenging mechanisms during pulmonary thromboembolism in rats. Thrombos Res 1993; 69: 101-11.
18. Young IS, Purvis JA, Lightbody JH, Adgey AA, Trimble ER. Lipid peroxidation and antioxidant status following thrombolytic therapy for acute myocardial infarction. Eur Heart J 1993; 14: 1027-33.
19. Sies H. Strategy of antioxidant defense. Eur J Biochern 1993; 215: 213-9.
20. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994; 74: 139-62.
21. Inoue M, Watanabe N, Matsuno K, Sasaki J, Tanaka Y, Hatanaka H, et al. Expression of a hybrid Cu/Zn-superoxide dismutase which has high affinity for heparin-like proteoglycans on vascular endothelial cells. J Biol Chem 1991; 266: 16409-14.
22. Karlsson K, Sandstrom J, Edlund SL, Marklund SL. Turnover of extracellular superoxide dismutase in tissues. Lab Invest 1994; 70: 705-10.
23. Matsushima T, Nakashima Y, Sugano M, Tasaki H, Kuroiwa A, Koide O. Suppression of atherosclerosis in hypercholesterolemic rabbits by chondroitin-6- sulphate. Artery 1987; 14: 316-37.
24. Morrison LM, Schjeide OA. Coronary Heart Disease and the Mucopolysaccharids (glycosaminoglycans), Charles C. Thomas: Springfiel, IL, 1974.
25. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
26. Bourin M-C, Lindahl U. Glycosaminoglicans and the regulation of blood coagulation. Biochem J 1993; 289: 313-30.
27. Heyderman RS, Klein NJ, Shennan GI, Levin M. Reduction of the anticoagulant activity of glycosaminoglycans on the surface of the vascular endothelium by endotoxin and neutrophils: evaluation by an amidolytic assay. Thromb Res 1992; 87: 677-85.
28. Danon D, Skutelsky E. Endothelial surface charge and its possible relationship to thrombogenesis. Ann NY Acad Sci 1976; 275: 47-63.
29. Bianchini P. Therapeutic potential of non-heparin glycosaminoglycans of natural origin. Semin in Thrombos Hemostas 1989; 15: 365-9.
30. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis. A multifactorial disease. Circulation 1993; 87 (Suppl 11): II-3 - II-16.
31. Lark MW, Yeo T-K, Mar H, Lara S, Hellstrom I, Hellstrom K-E, et al. Arterial chondroitin sulphate proteoglycan: localization with a monoclonal antibody. J Histochem Cytochem 1988; 36: 1211-21.
32. Forde RC, Fitzgerald DJ. Reactive oxygen species and platelet activation in reperfusion injury. Circulation 1997; 95: 787-9.
33. Hiraishi H, Terano A, Sugimoto T, Harada T, Razandi M, Ivey KJ. Protective role of intracellular superoxide dismutase against extracellular oxidants in cultured rat gastric cells. J Clin Invest 1994; 93: 331-8.
34. Halliwell B, Gutteridge JMC. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 1989; 246: 501-14.
35. Welch GN, Upchurch G Jr, Loscalzo J. Hyperhomocyst (e)inemia and atherosclerosis. Ann NY Acad Sci 1997; 811: 48-58.
36. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischaemia/reperfusion: resolved and unresolved issues. Circulation 1989; 80: 1115-27.
37. Opie LH. Reperfusion injury and its pharmacologic modification. Circulation 1989; 80: 1049-62.
38. Ambrosio G, Becker LC, Hutchings GM, Weisman HF, Weisfeldt ML. Reduction in experimental infarct size by recombinant human superoxide dismutase: insight into the pathophysiology of reperfusion injury. Circulation 1986; 74: 1424-33.
39. Vanhaecke J, Van de Werf F, Ronaszeki A, Flameng W, Lesaffre E, De Geest H. Effect of superoxide dismutase on infarct size and postischemic recovery of myocardial contractility and metabolism in dogs. J Am Coll Cardiol 1991; 18: 224-30.
40. Ma X-L, Johnson G III, Lefer AM. Low doses of superoxide dismutase and a stable prostacyclin analogue protect in myocardial ischaemia and reperfusion. J Am Coll Cardiol 1992; 19: 197-204.
41. Fujita T, Furutsu H, Nishikawa M, Takakura Y, Sezaki H, Hashida M. Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischaemia/reperfusion. Biochem Biophys Res Commun 1992; 189: 191-6.
42. Takakura Y, Mihara K, Hashida M. Control of the disposition profiles of proteins in the kidney via chemical modification. J Control Rel 1994; 28: 111-9.
43. Maksimenko AV. Thrombolysis research - new objectives after a shift of accent. Med Sci Monit 2002; 8: RA13-RA21.
44. Gebbink PK, Reynolds CH, Tollefsen DM, Mertcus K, Pannekoe, H. Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1. Biochemistry 1993; 32: 1675-80.
45. Fernandes F, N'guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-5.
46. Edelberg JM, Weissler M, Pizzo SV. Kinetic analysis of the effect of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation. Biochem J 1991; 276: 785-91.
47. Maksimenko AV, Terentieva EL, Konovalova OY, Torchilin VP. Interaction of chondroitin sulphate with enzymes. Ukranian Biochem J (in Russian) 1988; 60: 20-5.
48. Maksimenko AV, Tischenko EG. Covalent modification of superoxide dismutase subunits by chondroitin sulphate. Biochemistry (Moscow) 1997; 62: 1163-6.
49. Meng TT, Trachtenburg J, Ryan U, Abendschein DR. Potentiation of endogenous nitric oxide with superoxide dismutase inhibits platelet-mediated thrombosis in injured and stenotic arteries. J Am Coll Cardiol 1995; 25: 269-75.
50. Johnson A, Perlman MB, Blumenstock FA, Malik AB. Superoxide dismutase prevents the thrombin-induced increase in lung vascular permeability: role of superoxide in mediating the alterations in lung fluid balance. Ciculat Res 1986; 59: 405-15.
51. Igarashi R, Hoshino J, Takenaga M, Kawai S, Morizawa Y, Yasuda A, et al. Lecithinization of superoxide dismutase potentiates its protective effect against Forssman antiserum-induced elevation in guinea pig airway resistance. J Pharmacol Exp Ther 1992; 262: 1214-9.
52. Stralin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995; 15: 2032-6.
53. Adachi T, Yamada H, Yamada Y, Morichara N, Yamazaki N, Murakami T, et al. Substitution of glycine for arginine-213 in extracellular-superoxide dismutase impairs affinity for heparin and endothelial cell surface. Biochem J 1996; 313: 325-9.
54. Maksimenko AV. Modified preparations of superoxide dismutase and catalase to protect cardiovascular system and lungs. Uspechi Sovremennoy Biol (in Russian) 1993; 113: 351-65.
55. Laukkanen MO, Kivela A, Rissanen T, Rutanen J, Karkkainen MK, Leppanen, O, et al. Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2002; 106: 1999-2003.
56. Beresewisz A, Czarnowska E, Maczewski M. Ischemic preconditioning and superoxide dismutase protect against endothelium glycocalyx disruption in the postischemic guinea-pig hearts. Mol Cell Biochem 1998; 186: 87-97.
57. Czarnowska E, Karwatowska-Prokopczuk E. Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart. Basic Res Cardiol 1995; 90: 357-64.
58. Bohm T, Geiger M, Binder BR. Isolation and characterization of tissue-type plasminogen activator-binding proteoglycans from human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 1996; 16: 665-72.
59. Tomaru T, Fujimora Y, Morita T, Aoki N, Sakamoto Y, Nakamura F, et al. Local delivery of antithrombotic drug prevents restenosis after balloon angioplasty in atherosclerotic rabbit artery. Jpn Circ J 1996; 60: 981-92.
60. Berezin IV, Antonov VK, Martinek K. Eds, In: Immobilized Enzymes, Nauka: Moscow (in Russian) 1976; 1: 224-8.
61. Pratico D, Juliano L, Pulcinelli FM, Bonavita MS, Gazzaniga PP, Violi F. Hydrogen peroxide triggers activation of human platelets selectively exposed to nonaggregating concentrations of arachidonic acid and collagen. J Lab Clin Med 1992; 119: 364-70.
62. Leo R, Pratico D, Juliano L, Pulcinelli FM, Ghiselli A, Pignatelli P, et al. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenerated. Circulation 1997; 95: 885-91.
63. Hiraoka Y, Kishimoto C, Kurokawa M, Ochiani H, Sasayama S. Effect of polyethylene glycol conjugated superoxide dismutase on coxsackievirus B3 myocarditis in mice. Cardiovasc Res 1992; 26: 956-61.
64. McCord JM. Is iron sufficiency a risk factor in ischemic heart disease ? Circulation 1991; 83: 1112-4.
65. Hink HU, Samtanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, et al. Peroxidase properties of extracellular superoxide dismutase. Role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002; 22: 1402-8.
66. Maksimenko AV, Tischenko EG. Catalase modification by chondroitin sulphate. Biochemistry (Moscow) 1997; 62: 1167-70.
67. Donato JL, Marcondes S, Antunes E, Nogueira MD, Nader HB, Dietrich CP, et al. Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation. Br J Pharmacol 1996; 119: 1447-53.
68. Bingley JA, Campbell JH, Hayward IP, Campbell GR. Inhibition of neointimal formation of natural heparan sulphate proteoglycans of the arterial wall. Ann NY Acad Sci 1997; 811: 238-42.
69. Ambrosio G, Weisfeldt ML, Jacobus WE, Flaherty JT. Evidence for a reversible oxygen radical-mediated component of reperfusion injury: reduction by recombinant human superoxide dismutase administered at the time of reflow. Circulation 1987; 75: 282-91.
70. Chen LY, Nichols WW, Hendricks J, Mehta JL. Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombosis and thrombolysis. Amer Heart J 1995; 129: 211-8.
71. Falk E, Fernandes-Ortis A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 1995; 75: 51B-11B.
72. Tanaka K, Seuishi K. The coagulation and fibrinolysis system and atherosclerosis. Lab Invest 1993; 69: 5-18.
73. Fridovich I. Biological effects of the superoxide radical. Arch Biochem Biophys 1986; 247: 1-11.
74. Yim MB, Chock PB, Stadman ER. Copper, zinc superoxide dismutase catalyzes hydroxyl radical production from hydrogen peroxide. Proc Natl Acad Sci USA 1990; 87: 5006-10.
75. Marx JL. Oxygen free radicals linked to many diseases. Science 1987; 235: 529-31.
76. Simpson PJ, Mickelson JK, Lucchesi BR. Free radical scavengers in myocardial ischaemia. Federation Proc 1987; 46: 2413-21.
77. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
78. McCord JM. Oxygen-derived radicals: a link between reperfusion injury and inflammation. Federation Proc 1987; 46: 2402-6.
79. Bolli R. Superoxide dismutase 10 years later: a drug in search of a use. J Am Coll Cardiol 1991; 18: 231-3.
80. Patterson C, Madamanchi NR, Runge MS. The oxidative paradox. Another piece in the puzzle. Circ Res 2000; 87: 1074-6.
81. Semb AG, Ytrehus K, Vaage J, Mykleburst R, Mjos OD. Functional impairment in isolated rat hearts induced by activated leukocytes: protective effect of oxygen free radical scavengers. J Mol Cell Cardiol 1989; 21: 877-87.
82. Hagar JM, Hale SL, Ilvento JP, Kloner RA. Lack of significant effect of superoxide dismutase and catalase on development of reperfusion arrhythmias. Basic Res Cardiol 1991; 86: 127-35.
83. Naslund U, Haggmark S, Johansson G, Marklund SL, Refz S, Oberg A. Superoxide dismutase and catalase reduce infarct size in a porcine myocardial occlusion-reperfusion model. J Mol Cell Cardiol 1986; 18: 1077-84.
84. Przyklenk K, Kloner RA. "Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. Circ Res 1989; 64: 86-96.
85. Feeney RE. Chemical modification of proteins: comments and perspectives. Int J Pept Protein Res 1987; 27: 145-61.
86. Means GE, Feeney RE. Chemical modifications of proteins: history and application. Bioconjugate Chem 1990; 1: 2-12.
87. Mao GD, Thomas PD, Lopaschuk GD, Poznansky MJ. Superoxide dismutase (SOD) -catalase conjugates. Role of hydrogen peroxide and the Fenton reaction in SOD toxicity. J Biol Chem 1993; 268: 416-20.
88. Jerondi MO, Hertley CJ, Bolli R. Myocardial reperfusion injury: role of oxygen radicals and potential therapy with antioxidants. Am J Cardiol 1994; 73: 2B-7B.
89. Nissen NN, Shankar R, Gamelli RL, Singh A, DiPietro LA. Heparin and heparan sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. Biochem J 1999; 338: 637-42.
90. Maksimenko AV, Golubykh VL, Tischenko FG. Antithrombotic protection of the vascular wall by modified antioxidant enzymes. Metabolic Engineering Applied Systems Biology (II Ciocco, Castelvecchio Pascoli, Italy, October 6-11, 2002). Abstract Book 2002: PS II - No. 20.
91. Maksimenko AV, Golubykh VL, Tischenko EG. The combination of modified antioxidant enzymes for anti-thrombotic protection of the vascular wall: the significance of covalent connection of superoxide dismutase and catalase activities. J Pharmacy Pharmacol 2004; 56: 1463-8.
92. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Design 2004; 10(14): 1699-711.
93. Gruber A, Hanson SR. Potential new targets for antithrombotic therapy. Curr Pharm Design 2003; 9(28): 2367-74.
94. Vertuani S, Angusti A, Manfredini S. The antioxidants and pro-antioxidants network: an overview. Curr Pharm Design 2004; 10(14): 1677-94.